Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Techniques in Coloproctology
Published in: Techniques in Coloproctology 5/2013

01-10-2013 | Original Article

Hyperhomocysteinemia in patients with Crohn’s disease

Authors: G. Casella, E. Antonelli, C. Di Bella, E. Di Marco, M. Piatti, V. Villanacci, S. Bologna, V. Baldini, G. Bassotti

Published in: Techniques in Coloproctology | Issue 5/2013

Login to get access

Abstract

Background

Thromboembolic complications have been reported in patients with Crohn’s disease. Among the contributing factors, hyperhomocysteinemia has been described, although controversial data exist. The aim of our study was to assess the incidence of hyperhomocysteinemia in a nonselected group of patients with Crohn’s disease and to determine whether it might represent a risk marker for thrombosis in such patients.

Methods

Fifty consecutive patients were recruited, and clinical and laboratory variables were compared between those without and those with hyperhomocysteinemia. In the latter, gene mutations in N5-N10-methyltetrahydrofolate reductase were searched for, and clinical and laboratory variables were related to hyperhomocysteinemia. The presence/absence of thrombotic episodes in both groups was determined.

Results

Both groups had similar clinically active disease, with higher C-reactive protein values found in those with hyperhomocysteinemia. Hyperhomocysteinemia was found in 46 % of patients. Of these, 74 % had moderate, 13 % intermediate, and 13 % severe increase in serum homocysteine levels. No relationship was found between homocysteine levels, and age, vitamin B12 levels, folic acid levels, Crohn’s Disease Activity Index score, and CRP values. Gene mutations were found in 5 (22 %) patients, 2 homozygotes and 3 heterozygotes. None of the patients with or without hyperhomocysteinemia had episodes of venous or arterial thrombosis, or stroke.

Conclusions

Hyperhomocysteinemia is frequent in patients with Crohn’s disease, and it could be a cofactor for the pathogenesis of thrombotic episodes.
Literature
1.
Vrij AA, Rijken J, van Wersch JW, Stockbrügger RW (2003) Coagulation and fibrinolysis in inflammatory bowel disease and in giant cell arteritis. Pathophysiol Haemost Thromb 33:75–83PubMedCrossRef
2.
Grainge MJ, West J, Card TR (2010) Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 375:657–663PubMedCrossRef
3.
Kappelman MD, Horvath-Puho E, Sandler RS et al (2011) Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 60:937–943PubMedCrossRef
4.
Miehsler W, Reinisch W, Valic E et al (2004) Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 53:542–548PubMedCrossRef
5.
Cattaneo M, Vecchi M, Zighetti ML et al (1998) High prevalence of hyperhomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications? Thromb Haemost 80:542–545PubMed
6.
Mahmood A, Needham J, Prosser J et al (2005) Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease. Eur J Gastroenterol Hepatol 17:739–744PubMedCrossRef
7.
Oldenburg B, Fijnheer R, van der Griend R, vanBerge-Henegouwen GP, Koningsberger JC (2000) Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Am J Gastroenterol 95:2825–2830PubMedCrossRef
8.
Ray JG (1998) Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Int Med 158:2101–2106CrossRef
9.
Cattaneo M (1999) Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 81:165–176PubMed
10.
Oussalah A, Guéant JL, Peyrin-Biroulet L (2011) Meta-analysis: hyperhomocysteinemia in inflammatory bowel diseases. Aliment Pharmacol Ther 34:1173–1184PubMedCrossRef
11.
Satsangi J, Silverberg MS, Vermeire S, Colombel JF (2006) The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55:749–753PubMedCrossRef
12.
Stange EF, Travis SP, Vermeire S et al (2006) European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut 55(Suppl 1):i1–i15PubMedCrossRef
13.
Walters TD, Steinhart AH, Bernstein CN et al (2011) Validating Crohn’s disease activity indices for use in assessing postoperative recurrence. Inflamm Bowel Dis 17:1547–1556PubMedCrossRef
14.
Accinni R, Campolo J, Bartesaghi S et al (1998) High-performance liquid chromatographic determination of total plasma homocysteine with or without internal standards. J Chromatogr A 828:397–400PubMedCrossRef
15.
Casella G, Bassotti G, Villanacci V et al (2011) Is hyperhomocysteinemia relevant in patients with celiac disease? World J Gastroenterol 17:2941–2944PubMedCrossRef
16.
17.
Kluijtmans LA, van den Heuvel LP, Boers GH et al (1996) Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 58:35–41PubMed
18.
Kendall M (1938) A new measure of rank correlation. Biometrika 30:81–89
19.
Irving PM, Pasi KJ, Rampton DS (2005) Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol 3:617–628PubMedCrossRef
20.
Papa A, Scaldaferri F, Danese S et al (2008) Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. Dig Dis 26:149–155PubMedCrossRef
21.
Andersohn F, Waring M, Garbe E (2010) Risk of ischemic stroke in patients with Crohn’s disease: a population-based nested case-control study. Inflamm Bowel Dis 16:1387–1392PubMedCrossRef
22.
Spina L, Saibeni S, Battaglioli T, Peyvandi F, de Franchis R, Vecchi M (2005) Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. Am J Gastroenterol 100:2036–2041PubMedCrossRef
23.
Spek CA, ten Kate FJ, te Velde AA (2007) Factor V Leiden and the etiology of inflammatory bowel disease. Thromb Haemost 98:670–673PubMed
24.
Koutroubakis IE, Dilaveraki E, Vlachonikolis IG et al (2000) Hyperhomocysteinemia in Greek patients with inflammatory bowel disease. Dig Dis Sci 45:2347–2351PubMedCrossRef
25.
Bjerregaard LT, Nederby NJ, Fredholm L, Brandslund I, Munkholm P, Hey H (2002) Hyperhomocysteinaemia, coagulation pathway activation and thrombophilia in patients with inflammatory bowel disease. Scand J Gastroenterol 37:62–67PubMedCrossRef
26.
Saibeni S, Lecchi A, Meucci G et al (2005) Prevalence of hyperhomocysteinemia in adult gluten-sensitive enteropathy at diagnosis: role of B12, folate, and genetics. Clin Gastroenterol Hepatol 3:574–580PubMedCrossRef
27.
Peyrin-Biroulet L, Guéant-Rodriguez RM, Chen M, Bronowicki JP, Bigard MA, Guéant JL (2008) Association of MTRR 66A>G polymorphism with superoxide dismutase and disease activity in patients with Crohn’s disease. Am J Gastroenterol 103:399–406PubMedCrossRef
28.
Kallel L, Feki M, Sekri W et al (2011) Prevalence and risk factors of hyperhomocysteinemia in Tunisian patients with Crohn’s disease. J Crohns Colitis 5:110–114PubMedCrossRef
29.
Lambert D, Benhayoun S, Adjalla C et al (1996) Crohn’s disease and vitamin B12 metabolism. Dig Dis Sci 41:1417–1422PubMedCrossRef
30.
Roblin X, Germain E, Phelip JM et al (2006) Factors associated with hyperhomocysteinemia in inflammatory bowel disease: prospective study in 81 patients. Rev Med Interne 27:106–111PubMedCrossRef
31.
Saibeni S, Cattaneo M, Vecchi M et al (2003) Low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. Am J Gastroenterol 98:112–117PubMedCrossRef
32.
Younes-Mhenni S, Derex L, Berruyer M et al (2004) Large-artery stroke in a young patient with Crohn’s disease. Role of vitamin B6 deficiency-induced hyperhomocysteinemia. J Neurol Sci 221:113–115PubMedCrossRef
33.
Lipinski S, Bremer L, Lammers T, Thieme F, Schreiber S, Rosenstiel P (2011) Coagulation and inflammation Molecular insights and diagnostic implications. Hamostaseologie 31:94–102PubMedCrossRef
Metadata
Title
Hyperhomocysteinemia in patients with Crohn’s disease
Authors
G. Casella
E. Antonelli
C. Di Bella
E. Di Marco
M. Piatti
V. Villanacci
S. Bologna
V. Baldini
G. Bassotti
Publication date
01-10-2013
Publisher
Springer Milan
Published in
Techniques in Coloproctology / Issue 5/2013
Print ISSN: 1123-6337
Electronic ISSN: 1128-045X
DOI
https://doi.org/10.1007/s10151-013-0992-0

Other articles of this Issue 5/2013

Techniques in Coloproctology 5/2013 Go to the issue

Original Article

The association between prucalopride efficacy and constipation type

Trick of the Trade

Successful arterial reconstruction and colectomy to treat severe visceral arterial disease with concomitant colon cancer

Invited Comment

Invited comment on Hultén et al.: Sacral nerve stimulation (SNS), posterior tibial nerve stimulation (PTNS) or acupuncture for the treatment for fecal incontinence: a clinical commentary

Original Article

Efficacy of cyclic sacral nerve stimulation for faecal incontinence

Editorial

Imaging in patients with obstructed defecation

Original Article

Post-colectomy assessment of gastrointestinal function: a prospective study on colorectal cancer patients